Cargando…

Baricitinib for patients with severe COVID-19—time to change the standard of care?

Detalles Bibliográficos
Autores principales:	Supady, Alexander, Zeiser, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813061/ https://www.ncbi.nlm.nih.gov/pubmed/35123659 http://dx.doi.org/10.1016/S2213-2600(22)00021-2

Ejemplares similares

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality
por: Mehta, Puja, et al.
Publicado: (2022)

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
por: Kalil, Andre C, et al.
Publicado: (2021)

Should we ration extracorporeal membrane oxygenation during the COVID-19 pandemic?
por: Supady, Alexander, et al.
Publicado: (2021)

Severe COVID-19 in pregnancy is almost exclusively limited to unvaccinated women – time for policies to change
por: Engjom, Hilde, et al.
Publicado: (2022)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

On the Use of Hemadsorption with CytoSorb in Patients with Septic Shock. Comment on Kogelmann et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock. J. Clin. Med. 2021, 10, 2939
por: Supady, Alexander, et al.
Publicado: (2022)

Severe COVID-19 pneumonitis and timing of birth in women
por: Calvert, Clara, et al.
Publicado: (2023)

Disease surveillance for the COVID-19 era: time for bold changes
por: Morgan, Oliver W, et al.
Publicado: (2021)

COVID-19 pandemic reveals the peril of ignoring metadata standards
por: Schriml, Lynn M., et al.
Publicado: (2020)

COVID-19, climate change, and communities
por: Sacks, Emma, et al.
Publicado: (2021)

Standards of care in mesothelioma treatment
por: Harden, Susan V., et al.
Publicado: (2020)

Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States
por: Ohsfeldt, Robert, et al.
Publicado: (2021)

Zero separation: infant and family-centred developmental care in times of COVID-19
por: Kostenzer, Johanna, et al.
Publicado: (2022)

Azithromycin for severe COVID-19
por: Oldenburg, Catherine E, et al.
Publicado: (2020)

NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
Publicado: (2021)

Triage in the time of COVID-19
por: Gilbert, Allison, et al.
Publicado: (2022)

Cancer care in the Commonwealth Caribbean in COVID times
por: Andall-Brereton, Glennis, et al.
Publicado: (2020)

498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Time for a standardized system of reporting sites of genomic methylation
por: Saffery, Richard, et al.
Publicado: (2015)

No time for complacency on COVID-19 in Europe
por: Flahault, Antoine, et al.
Publicado: (2023)

Caring for our cancer patients in the wake of COVID-19
por: El-Shakankery, Karim Hussien, et al.
Publicado: (2020)

Observational research on severe COVID-19 in diabetes
por: Stehouwer, Coen D A
Publicado: (2021)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

A decade after the metabolomics standards initiative it's time for a revision
por: Spicer, Rachel A., et al.
Publicado: (2017)

Health care for chronic neurological patients after COVID-19
por: Antonini, Angelo
Publicado: (2020)

The time to do serosurveys for COVID-19 is now
por: Peeling, Rosanna W, et al.
Publicado: (2020)

Offline: Health in the unhappy time of COVID-19
por: Horton, Richard
Publicado: (2020)

Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019
por: Tziolos, Nikolaos, et al.
Publicado: (2021)

Sulfasalazine: a risk factor for severe COVID-19?
por: Konig, Maximilian F, et al.
Publicado: (2022)

The effects of antihypertensive medications on severity and outcomes of COVID19
por: Agirbasli, Mehmet
Publicado: (2022)

Clinical course and mortality risk of severe COVID-19
por: Weiss, Paul, et al.
Publicado: (2020)

Epidemiology of severe COVID-19 from South Africa
por: Madhi, Shabir A, et al.
Publicado: (2021)

Are women with asthma at increased risk for severe COVID-19?
por: Fernando, Mario, et al.
Publicado: (2021)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
por: Shapiro, Adrienne E, et al.
Publicado: (2022)

Awake prone positioning in COVID-19: is tummy time ready for prime time?
por: Weatherald, Jason, et al.
Publicado: (2021)

Floods in China, COVID-19, and climate change
por: Guo, Yuming, et al.
Publicado: (2020)

Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy
por: Brunetti-Pierri, Nicola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j0gljj02s7g4kn0n3uj229g1pg